Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (381-390 of 692) with videos related to

Pageof 70
Sort By:
Journal of Ethnopharmacology|October 12, 2000
Immunomodulatory and anti-inflammatory activity of Picrorhiza scrophulariifloraH F Smit, B H Kroes, A J van den Berg, et al.
EJNMMI Research|February 9, 2019
Repeatability of [<sup>18</sup>F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patientsGuilherme D Kolinger, David Vállez García, Gerbrand M Kramer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Molecular Cancer Therapeutics|February 18, 2010
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinibElisa Giovannetti, Paolo A Zucali, Godefridus J Peters, et al.
EJNMMI Research|April 9, 2015
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing micePaul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2016
A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine TumorsJules L Derks, Robert Jan van Suylen, Erik Thunnissen, et al.
Journal of Proteomics|February 3, 2019
Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response predictionFranziska Böttger, Tieneke B Schaaij-Visser, Inge de Reus, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 30, 2009
A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutationsD Kramer, F B Thunnissen, M I Gallegos-Ruiz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 7, 2013
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patientsEline E Verwer, Floris H P van Velden, Idris Bahce, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 22, 2008
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomographyAdrianus J de Langen, Bianca Klabbers, Mark Lubberink, et al.
Pageof 70

Showing results (381-390 of 692) with videos related to

Sort By:
Pageof 70
Journal of Ethnopharmacology|October 12, 2000
Immunomodulatory and anti-inflammatory activity of Picrorhiza scrophulariifloraH F Smit, B H Kroes, A J van den Berg, et al.
EJNMMI Research|February 9, 2019
Repeatability of [<sup>18</sup>F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patientsGuilherme D Kolinger, David Vállez García, Gerbrand M Kramer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Molecular Cancer Therapeutics|February 18, 2010
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinibElisa Giovannetti, Paolo A Zucali, Godefridus J Peters, et al.
EJNMMI Research|April 9, 2015
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing micePaul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2016
A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine TumorsJules L Derks, Robert Jan van Suylen, Erik Thunnissen, et al.
Journal of Proteomics|February 3, 2019
Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response predictionFranziska Böttger, Tieneke B Schaaij-Visser, Inge de Reus, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 30, 2009
A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutationsD Kramer, F B Thunnissen, M I Gallegos-Ruiz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 7, 2013
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patientsEline E Verwer, Floris H P van Velden, Idris Bahce, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 22, 2008
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomographyAdrianus J de Langen, Bianca Klabbers, Mark Lubberink, et al.
Pageof 70